Want to join the conversation?
$AGN said that in 2016, the company expects more than a dozen approvals and regulatory submissions and is on track to achieve these targets. On the generics business, $AGN said that out of all of first-to-files published by FDA in 2016, the company's generic team holds 50% of those accepted.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.